KR20120080579A - 암 치료와 예방에 있어 메트포르민의 사용 - Google Patents

암 치료와 예방에 있어 메트포르민의 사용 Download PDF

Info

Publication number
KR20120080579A
KR20120080579A KR1020127007261A KR20127007261A KR20120080579A KR 20120080579 A KR20120080579 A KR 20120080579A KR 1020127007261 A KR1020127007261 A KR 1020127007261A KR 20127007261 A KR20127007261 A KR 20127007261A KR 20120080579 A KR20120080579 A KR 20120080579A
Authority
KR
South Korea
Prior art keywords
metformin
cancer
cells
tumor
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127007261A
Other languages
English (en)
Korean (ko)
Inventor
케빈 슈트룰
헤더 허쉬
디미트리오스 일리오폴로스
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Publication of KR20120080579A publication Critical patent/KR20120080579A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127007261A 2009-08-25 2010-08-25 암 치료와 예방에 있어 메트포르민의 사용 Withdrawn KR20120080579A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23677809P 2009-08-25 2009-08-25
US61/236,778 2009-08-25

Publications (1)

Publication Number Publication Date
KR20120080579A true KR20120080579A (ko) 2012-07-17

Family

ID=43733025

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007261A Withdrawn KR20120080579A (ko) 2009-08-25 2010-08-25 암 치료와 예방에 있어 메트포르민의 사용

Country Status (14)

Country Link
US (1) US20120220664A1 (enExample)
EP (1) EP2470170A4 (enExample)
JP (1) JP2013503171A (enExample)
KR (1) KR20120080579A (enExample)
CN (1) CN102596192A (enExample)
AU (1) AU2010292599A1 (enExample)
BR (1) BR112012004281A2 (enExample)
CA (1) CA2772120A1 (enExample)
IL (1) IL218287A0 (enExample)
IN (1) IN2012DN01964A (enExample)
MX (1) MX2012002337A (enExample)
SG (1) SG178556A1 (enExample)
WO (1) WO2011031474A2 (enExample)
ZA (1) ZA201201434B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130040310A1 (en) * 2009-12-15 2013-02-14 Salk Institute For Biological Studies Ulk1 compositions, inhibitors, screening and methods of use
BR112013014076A2 (pt) * 2010-12-06 2016-11-22 Cure Cancer Worldwide Corp métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
US9532984B2 (en) * 2011-06-10 2017-01-03 The Translational Genomics Research Institute Therapeutic combination for cancer treatment
CN102327256B (zh) * 2011-09-22 2014-01-29 上海交通大学医学院附属瑞金医院 二甲双胍在制备治疗淋巴瘤疾病药物中的应用
WO2013086002A1 (en) * 2011-12-05 2013-06-13 Cellworks Research India Private Limited Compositions, process of preparation of said compositions and method of treating cancer
CA3159085A1 (en) * 2013-01-14 2014-07-17 Clinics Operations Limited Combination cancer therapeutics and uses thereof
BR112015024537B1 (pt) * 2013-04-12 2022-09-06 Ned Biosystems, Inc Uso de (i) ciclofosfamida, (ii) metformina, (iii) curcumina, (iv) melatonina, (v) naltrexona, (vi) ácido alfa lipoico e (vii) genisteína e combinação no tratamento de câncer
JP6242071B2 (ja) * 2013-04-23 2017-12-06 国立大学法人 岡山大学 免疫疲弊ｃｄ８＋ｔ細胞の機能改善薬、がん治療薬及びメタボリック症候群の予防または治療薬
JP6440212B2 (ja) 2013-05-24 2018-12-19 株式会社加齢・栄養研究所 メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CN107205968B (zh) * 2014-08-14 2021-08-20 威斯康星州医药大学股份有限公司 修饰的线粒体-二甲双胍化合物及其合成和使用方法
EP3232199B1 (en) * 2014-08-19 2022-05-04 National University Corporation Okayama University Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
WO2016026933A1 (en) * 2014-08-21 2016-02-25 Centre National De La Recherche Scientifique - Cnrs - Adjuvant or neoadjuvant therapy for sensitizing cancer stem cells to chemotherapy
WO2017142485A1 (en) * 2016-02-16 2017-08-24 Agency For Science, Technology And Research Cancer epigenetic profiling
CA3059210C (en) * 2016-05-19 2022-07-19 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
CN106727468A (zh) * 2017-04-01 2017-05-31 四川大学 二甲双胍及联合二甲双胍和长春新碱在制备治疗白血病药物中的应用及药物组合物
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213764A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
CA3063717C (en) 2017-05-19 2021-08-24 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019183003A1 (en) * 2018-03-18 2019-09-26 The University Of North Carolina At Chapel Hill Methods and assays for endometrial diseases
CN117338938A (zh) * 2019-02-28 2024-01-05 北京强新生物科技有限公司 用于治疗中枢神经系统紊乱的组合疗法
KR102312100B1 (ko) * 2020-06-05 2021-10-14 (주)프론트바이오 항바이러스제 및 항우울제를 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물
WO2024233616A1 (en) * 2023-05-11 2024-11-14 Wainer Irving W Method for treating cancer
WO2025085311A1 (en) * 2023-10-16 2025-04-24 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of kmt2d-deficient cancers
WO2025157212A1 (zh) * 2024-01-23 2025-07-31 成都夸常奥普医疗科技有限公司 包含n，n-二甲基亚双胍的制剂、和包含n,n-二甲基亚双胍与药物的药物组合、组合物、试剂盒及其用途和制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799263A4 (en) * 2004-09-15 2009-07-29 Harvard College REDUCTION OF ER-STRESS IN THE TREATMENT OF ADIPOSITAS AND DIABETES
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
DE102006026026A1 (de) * 2006-06-01 2007-12-06 Grünenthal GmbH Arzneimittel
US20080188457A1 (en) * 2007-02-02 2008-08-07 Braincells, Inc. Modulation of Neurogenesis with Biguanides and GSK3-beta Agents
WO2008110491A2 (en) * 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
WO2009101199A2 (en) * 2008-02-15 2009-08-20 Bodo Melnik Treatment of acne vulgaris; rosacea and rhinophym

Also Published As

Publication number Publication date
SG178556A1 (en) 2012-03-29
US20120220664A1 (en) 2012-08-30
CN102596192A (zh) 2012-07-18
IL218287A0 (en) 2012-04-30
WO2011031474A2 (en) 2011-03-17
JP2013503171A (ja) 2013-01-31
CA2772120A1 (en) 2011-03-17
IN2012DN01964A (enExample) 2015-08-21
BR112012004281A2 (pt) 2016-03-08
EP2470170A4 (en) 2013-01-02
AU2010292599A1 (en) 2012-03-15
EP2470170A2 (en) 2012-07-04
MX2012002337A (es) 2012-06-25
WO2011031474A3 (en) 2011-06-16
ZA201201434B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
KR20120080579A (ko) 암 치료와 예방에 있어 메트포르민의 사용
ES2863996T3 (es) Terapia de combinación para el tratamiento del cáncer
Jia et al. Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo
Aranda et al. Nitric oxide and cancer: the emerging role of S-nitrosylation
Kai et al. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin
JP2024128025A (ja) ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用
EP3268087A1 (en) METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
EP2968379B1 (en) Etoposide prodrugs for use in targeting cancer stem cells
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
KR20190084291A (ko) 암 치료를 위한 제약 조성물 및 방법
WO2020230701A1 (ja) 抗腫瘍剤及び配合剤
Kiziltepe et al. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo
JP2017527615A (ja) 線維化疾患及び癌を治療するための組成物及び方法
KR20190089191A (ko) 티로신 유도체 및 이들을 포함하는 조성물
US11583509B2 (en) Compound for treating cancer and diabetes
JP2021517886A (ja) 口腔癌治療用の医薬の製造ためのジンセノサイドｍ１の使用
WO2014085485A1 (en) Methods and compositions for targeting cancer stem cells
US10792331B2 (en) Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
HK1173378A (en) Use of metformin in cancer treatment and prevention
O’Connor et al. New drugs for the treatment of advanced-stage diffuse large cell lymphomas
Vasudevan et al. Efficacy of Pazopanib on Primary Patient-derived Undifferentiated Malignant Round Cell Sarcoma Line
Yang et al. Gallium maltolate and cisplatin co-treatment effectively targets triple-negative breast cancer in spheroid and mouse models
HK40061465A (en) Inos-inhibitory compositions and their use as breast cancer therapeutics
CN110627733A (zh) 一种抗肿瘤小分子化合物的作用机制及应用
Scott Bryostatin-1, an effective anti-tumour agent when applied individually and in combination

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid